Current Report Filing (8-k)
March 25 2022 - 4:29PM
Edgar (US Regulatory)
0001419051
false
0001419051
2022-03-25
2022-03-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 25, 2022
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in its Charter)
Nevada |
|
000-54554 |
|
45-1226465 |
(State
or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification Number) |
701
Wild Rose Lane |
Elk
City, Idaho 83525 |
(Address
of Principal Executive Offices and Zip Code) |
(760)
295-7208 |
(Issuer’s
telephone number) |
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock |
|
TSOI |
|
OTC Markets |
Item
1.01 Entry into a Material Definitive Agreement.
On
March 24, 2022, Office of Technology Transfer, University of Miami, and Therapeutic Solutions International, Inc. entered into an Asset
Transfer and License Agreement. The material information relevant to public disclosure is the following: Within ten (10) days of the
Effective Date, 1) TSOI shall make an initial payment of two hundred thousand dollars ($200,000) to UM; 2) Within six (6) months of the
Effective Date, TSOI shall make a second payment of one million eight hundred thousand dollars ($1,800,000) (at the completion of the
primary endpoint of the phase 2b/3 clinical trial specified in the IND or (ii) one (1) year from the Effective Date), and 3) TSOI shall
make a final payment of two million dollars ($2,000,000). In turn TSOI replaces UM as Sponsor, receives all trial doses, and appoints
James Veltmeyer, MD, Chief Medical Officer as Principal Investigator.
Item
9.01 Financial Statements and Exhibits.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
March 25, 2022 |
|
|
|
|
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
|
|
|
|
By:
|
/s/
Timothy Dixon |
|
|
Timothy
Dixon |
|
|
Chief
Executive Officer |
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024